Another phase III (CALGB 90206)(26) randomized trial enrolled 732 previously untreated metastatic RCC patients for bevacizumab (10 mg/kg each 2 weeks) plus IFN-α (9 million U/3 times weekly) versus IFN-α monotherapy. The gene discussed is IFNA17; the disease is renal cell carcinoma.